Investors unmoved with Boston Scientific’s growth plans, shares down 2%

At its Investor Day event in New York today, Boston Scientific (BSX -1.9%) presented its plans for long-term growth. Key points:

Plans to launch ~75 new products by 2022. Also by then, moderate/high-growth markets should represent ~80% of sales.

6 – 9% targeted compound annual revenue growth rate for 2020 – 2022. Double-digit non-GAAP EPS growth with 50-100 basis point improvement per year in operating margin for the years 2019 – 2022.

Strong non-GAAP free cash flow to be maintained.

https://seekingalpha.com/news/3473942-investors-unmoved-boston-scientifics-growth-plans-shares-2-percent